Corpus Intelligence IC Memo — CROUSE HOSPITAL 2026-04-26 09:07 UTC
IC Memo — CROUSE HOSPITAL
Investment Committee Memorandum | NY | 502 beds | Grade C | EBITDA uplift $37.2M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

CROUSE HOSPITAL

CCN 330203 | ONONDAGA, NY | 502 beds | April 26, 2026
EBITDA BridgeData Room
C
Investability

1. Target Overview & Investment Thesis

CROUSE HOSPITAL is a 502-bed suburban community hospital in ONONDAGA, NY with $505.9M in net patient revenue and a -0.7% operating margin. The hospital serves a payer mix of 20.0% Medicare, 5.4% Medicaid, and 74.6% commercial.

Thesis: Undervalued. Our ML models identify $37.2M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -0.7% to 6.7% (+736bps).

Net Revenue HCRIS$505.9M
Current EBITDA COMPUTED$-3.4M
Operating Margin COMPUTED-0.7%
Occupancy HCRIS67.5%
Revenue / Bed COMPUTED$1.0M
Net-to-Gross HCRIS49.3%
Distress Probability ML47.8%

2. Market Context & Competitive Position

196
NY Hospitals
-17.5%
State Median Margin
59
Comparable Hospitals

NY has 196 Medicare-certified hospitals with a median operating margin of -17.5%. The target's margin of -0.7% places it above the state median. Among 59 size-comparable peers (251-1004 beds), the median margin is -17.7%. The target performs in line with or above peers.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (251-1004), prioritizing same-state peers. 59 hospitals in the comp set.

HospitalStateBedsRevenueMargin
CROUSE HOSPITAL (Target)NY502$505.9M-0.7%
MEMORIAL HOSPITAL FOR CANCER ANY514$4.34B-32.5%
STRONG MEMORIAL HOSPITALNY749$3.31B5.2%
NORTH SHORE UNIVERSITY HOSPITANY782$2.27B-50.0%
STONY BROOK UNIVERSITY HOSPITANY725$1.90B-4.9%
WESTCHESTER MEDICAL CENTERNY696$1.63B2.6%
KALEIDA HEALTHNY954$1.38B-8.8%
UNIVERSITY HOSPITAL AT SYRACUSNY625$1.33B-17.2%
LENOX HILL HOSPITALNY415$1.32B-35.1%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $37.2M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$10.6M+210bp18mo
Cost to Collect4.5%2.5%$10.1M+200bp12mo
Denial Rate Reduction12.0%6.5%$10.0M+198bp12mo
A/R Days Reduction5200.0%3800.0%$6.2M+122bp9mo
Clean Claim Rate88.0%96.0%$324K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$10.6M
Cost to Collect
$10.1M
Denial Rate Reduction
$10.0M
A/R Days Reduction
$6.2M
Clean Claim Rate
$324K
Total EBITDA Uplift$37.2M
Current EBITDA$-3.4M
+ RCM Uplift+$37.2M
Pro Forma EBITDA$33.8M
Current Margin-0.7%
Pro Forma Margin6.7%
WC Released (1x)$19.4M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$-5.3M$349.7M0.00x-100.0%
Base (11x exit)10.0x11.0x$-5.3M$383.0M0.00x-100.0%
Bull Case9.0x11.0x$-4.8M$504.1M0.00x-100.0%
Bull (12x exit)9.0x12.0x$-4.8M$548.6M0.00x-100.0%
Bear Case11.0x10.0x$-5.8M$165.2M0.00x-100.0%
Bear (11x exit)11.0x11.0x$-5.8M$179.9M0.00x-100.0%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
HighNegative operating marginRCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 59 hospitals with 251-1004 beds
  • Same-state prioritization (n=60)
  • Comp margins: P25=-26.6% / P50=-17.7% / P75=-9.2%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.